Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained a Neutral rating on Humacyte (NASDAQ:HUMA) but reduced the price target from $3.5 to $3.
November 10, 2023 | 10:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Humacyte while lowering the price target from $3.5 to $3.
The reduction in price target by Piper Sandler suggests a less optimistic outlook on Humacyte's stock value, which could lead to a negative perception among investors and potentially decrease the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100